The TASC Trial: Therapeutic vs Prophylactic Anticoagulation for Acute Chest Syndrome
For adults with ACS and no evidence of pulmonary artery macrothrombosis, consider escalating anticoagulation to therapeutic doses if the patient is refractory to standard supportive care. The data support this approach by showing reduced time to resolution and lower opioid needs compared to prophylactic dosing. However, remember that this trial was specific to tinzaparin, so caution is warranted when extrapolating these dose recommendations to other agents.
The TASC trial represents a significant step forward by being the first phase 3 randomized controlled trial to directly compare therapeutic versus prophylactic-dose tinzaparin for managing acute chest syndrome (ACS) in adults with sickle cell disease who do not have pulmonary artery macrothrombosis. The primary finding was that using therapeutic-dose tinzaparin successfully reduced the overall duration of ACS when compared to standard prophylactic dosing. Furthermore, this higher dose regimen was associated with a clinically meaningful reduction in opioid consumption among patients. These results suggest that simply maintaining prophylaxis might be suboptimal for some patients presenting with ACS.